Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Though specifics of the order were not clear, shares of all large drugmakers, J&J, Eli Lilly, Pfizer, Merck, Gilead, Bristol-Myers, Amgen and several other U.S. pharmaceutical stocks were on the ...

For key players in the sector, Eli Lilly has a median analyst target that’s 22% above its current share price. UnitedHealth Group is expected to rise by 18%, while Merck & Co. is forecasted 27% ...

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.

That growth began last year with Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO). GLP-1 receptor agonist drugs commercialized by those firms have started a revolution in weight loss.

Nearly all hormone shipments were sent to Indiana, home to Eli Lilly's headquarters. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

A cautious culture cost Novo its obesity lead Danish drugmaker Novo Nordisk was the first to sell a new generation of GLP-1 obesity drugs, but it’s now widely seen as trailing Eli Lilly. How did ...